Open

Metastatic Triple Negative Breast Cancer Study

We are studying how well a new medicine called Sacituzumab Tirumotecan works by itself and when combined with another medicine called pembrolizumab. We are comparing these treatments to the usual chemotherapy to see which one is better and safer for people with a specific type of breast cancer that has come back or spread and can't be removed by surgery.

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

The study will require blood draws, visits with your oncologist or someone on their team, and chemotherapy infusions.

Total length of participation:
2 years

Looking for Specific Volunteers

Able to participate:

You have locally recurrent unresectable or metastatic TNBC that cannot be treated with curative intent
You have not received systemic treatment for locally recurrent unresectable or metastatic TNBC

Not eligible if:

You have breast cancer amenable to treatment with curative intent
You have received prior systemic therapy for treatment of locally recurrent unresectable or metastatic TNBC
You have moderate to severe peripheral neuropathy
You have significant and/or uncontrolled cardiovascular disease
You have severe dry eye

Contact the Team

Visit Location

Contact & Visit Location

Additional Study Information

Principal Investigator

Julia Rauch
UNC Hospitals - Rex

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Breast)

IRB Number

25-0557

ClinicalTrials.gov

NCT06841354

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.